Profectus Bio wins $200K grant for HIV therapies
Baltimore, Md.-based Profectus BioSciences, a biotech developing new strategies to attack HIV, received a $200,000 small-business innovation grant from the National Institutes of Health to improve the effectiveness of anti-HIV antibodies. Last month, the company received a similar $300,000 grant (PDF link), just a few days after the company raised $3 million in a private placement.
Profectus, which was spun out of the Institute for Human Virology in 2005, has so far rased a total of at least $6.5 million.
Next Story: McKesson acquires health-IT firm Awarix
Previous Story: ConnectivHealth, yet another online health-info provider, raises $2.1M
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
